🇺🇸 FDA
Pipeline program

ARQ-151 cream 0.05%

ARQ-151-218

Phase 2 small_molecule completed

Quick answer

ARQ-151 cream 0.05% for Atopic Dermatitis (Eczema) is a Phase 2 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Atopic Dermatitis (Eczema)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials